אביטרקסט טבע

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

METHOTREXATE

Disponível em:

ABIC MARKETING LTD, ISRAEL

Código ATC:

L01BA01

Forma farmacêutica:

תמיסה להזרקה

Composição:

METHOTREXATE 25 MG/ML

Via de administração:

תוך-שרירי, תוך-ורידי, תוך-שדרתי, תוך-עורקי, תוך חדרי

Tipo de prescrição:

מרשם נדרש

Fabricado por:

PHARMACHEMIE B.V., (TEVA GROUP) ,THE NETHERLANDS

Grupo terapêutico:

METHOTREXATE

Área terapêutica:

METHOTREXATE

Indicações terapêuticas:

Antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. Palliation of acute lymphocytic leukemia. Abitrexate is also indicated in the treatment and prophylaxis of meningeal leukemia. Greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. In combination with other anticancer agents, Abitrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. Abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. Abitrexate is effective in the treatment of the advanced stages (III and IV Peter's Staging System) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. Psoriasis: because of the high risk attending its use, Abitrexate is

Data de autorização:

2015-02-28